Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence

Pharmacotherapy

Volumn 37, Issue 5, 2017, Pages 579-592

  Yim, Juwon ^a,d   Smith, Jordan R ^b   Rybak, Michael J ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HIGH POINT UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

combination therapy; daptomycin; double lactam combinations; linezolid; quinupristin dalfopristin; tigecycline; vancomycin resistant Enterococcus faecium

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; ORITAVANCIN; RIFAMPICIN; TEDIZOLID; TIGECYCLINE; VANCOMYCIN; TEICOPLANIN; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; IN VITRO STUDY; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NONHUMAN; PHARMACODYNAMICS; REVIEW; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM BACTEREMIA; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM MENINGITIS; WOUND INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; CASE REPORT; COMBINATION DRUG THERAPY; CROSS INFECTION; DRUG EFFECTS; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; PHYSIOLOGY; VANCOMYCIN RESISTANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 85019113320     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1922     Document Type: Review

References (74)

1. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 2013;1:1–14.
2. Hayakawa K, Martin ET, Gudur UM, et al. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. Antimicrob Agents Chemother 2014;7:3968–75.
3. Billington EO, Phang SH, Gregson DB, et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis 2014;76–82.
4. Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case–control study. Infection 2004;2:72–7.
5. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;15:1435–86.
6. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;2:586–9.
7. Padmasini E, Padmaraj R, Ramesh SS. High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates of Enterococcus species in Chennai, India. ScientificWorldJournal 2014;2014:329157.
8. Tsakris A, Pournaras S, Maniatis AN, Douboyas J, Antoniadis A. Increasing prevalence of high-level gentamicin resistance among Enterococci isolated in Greece. Chemotherapy 2001;2:86–9.
9. Fernandez-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013;9:1261–8.
10. Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther 2011;3:a2466.
11. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;3:327–33.
12. Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis 2016;10:1242–50.
13. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006;S25–34.
14. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;2:210–9.
15. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012;4:266–78.
16. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev 2006;5:673–91.
17. Rice LB. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012;2:198–208.
18. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;8:2538–44.
19. Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 2012;17:4494–504.
20. Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis 2017;64:605–13.
21. Lexicomp Online. Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; January 29, 2017.
22. Sader HS, Farrell DJ, Flamm RK, Jones RN. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005–2012). Int J Antimicrob Agents 2014;5:465–9.
23. Judge T, Pogue JM, Marchaim D, et al. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Infect Control Hosp Epidemiol 2012;12:1250–4.
24. Clinical and Laboratory Standards Institute. M100-S25 performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement; 2015.
25. Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013;9:4190–6.
26. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;5:1598–603.
27. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012;8:4354–9.
28. Werth BJ, Steed ME, Ireland CE, et al. Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis. Antimicrob Agents Chemother 2014;9:5253–61.
29. Shukla BS, Shelburne S, Reyes K, et al. Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint? Clin Infect Dis 2016;12:1514–20.
30. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011;10:892–900.
31. Tran TT, Panesso D, Mishra NN, et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 2013;4:e00281–13.
32. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008;1:269–78.
33. Yang SJ, Xiong YQ, Dunman PM, et al. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 2009;6:2636–7.
34. Rybak JM, Barber KE, Rybak MJ. Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother 2013;14:1919–32.
35. Liu Y, Wang Y, Schwarz S, et al. Transferable multiresistance plasmids carrying cfr in Enterococcus spp. from swine and farm environment. Antimicrob Agents Chemother 2013;1:42–8.
36. Sahm DF, Deane J, Bien PA, et al. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 2015;2:112–8.
37. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am 2009;4:965–82, ix.
38. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002;6:1845–50.
39. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother 1997;5:931–5.
40. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006;8:1099–110.
41. Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 2013;1:122–3.
42. Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009–2010. Antimicrob Agents Chemother 2012;3:1639–42.
43. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;2:158–63.
44. Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012;2:838–44.
45. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2015;6:1738–43.
46. Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014;3:1494–500.
47. Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 2014;8:2148–54.
48. Smith JR, Barber KE, Raut A, Rybak MJ. beta-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother 2015;5:2842–8.
49. Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013;3:1518–20.
50. Hall AD, Werth BJ, McRoberts JP, Rybak MJ. A preliminary Evaluation of Daptomycin Plus Fosfomycin (FOS) Against Vancomycin-Resistant Enterococcus faecium (VREFm) and faecalis (VREFs) using an in vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Bacteremia Model. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012.
51. ClinicalTrials.gov. Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections (ZEUS), January 12, 2017. Available from https://clinicaltrials.gov/ct2/show/NCT02753946?term=fosfomycin&rank=20. Accessed January 25, 2017.
52. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001;6:432–4.
53. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;3:689–90.
54. Luther MK, Arvanitis M, Mylonakis E, LaPlante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother 2014;8:4612–20.
55. Knoll BM, Hellmann M, Kotton CN. Vancomycin-resistant Enterococcus faecium meningitis in adults: case series and review of the literature. Scand J Infect Dis 2013;2:131–9.
56. Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002;8:2606–12.
57. Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother 2008;3:629–35.
58. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;4:1664–5.
59. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;1:92–8.
60. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998;10:2710–7.
61. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998;6:1554–6.
62. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis 2000;2:403–4.
63. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001;11:3202–4.
64. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004;6:989–91.
65. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003;8:818–20.
66. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;6:555–62.
67. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;5:343–4.
68. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009;12:2108–12.
69. Pontikis K, Pefanis A, Tsaganos T, Tzepi IM, Carrer DP, Giamarellou H. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium. Antimicrob Agents Chemother 2013;7:3392–4.
70. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;12:1517–23.
71. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin–United States, 1989–1993. MMWR Morb Mortal Wkly Rep 1993;30:597–9.
72. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015;217–30.
73. Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. Clin Infect Dis 2015;6:871–8.
74. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013;8:4042–5.